Anna Sipitanou
Business Development Manager

About

Anna Sipitanou holds a BSc in Chemistry and an MSc in Drug Discovery & Pharmaceutical Sciences. Having joined Copley Scientific in 2017, Ms Sipitanou plays a key role in the company’s technical and sales support services, including the training of customers on a wide range of pharmaceutical testing equipment, with a particular focus on OINPD testing. Having worked closely with pharmaceutical companies on a wide range of OINDP projects, Ms Sipitanou has gained specialist knowledge of the regulatory requirements for both delivered dose uniformity and aerodynamic particle size distribution testing, as well as extensive experience in methods to improve in vitro–in vivo correlations (IVIVC) and other specialist testing applications, including generic drug development, inhaled dissolution and facemask testing.

Contributions

NASAL

IMPROVING IN VITRO TEST METHODS FOR NASAL DRUG PRODUCTS

Mark Copley and Anna Sipitanou look at how in vitro testing is being refined for greater repeatability to maximise its value as a low-cost tool for product development, including an assessment of the role of automation in improving the sensitivity of in vitro testing.

More contributions

PULMONARY

SEMI-AUTOMATION IN INHALER TESTING – EXPLORING THE POTENTIAL AND PRACTICALITIES

João Pereira, Raquel Borda D’Água, Mark Copley and Anna Sipitanou, discuss the semi-automation of cascade impactor testing and the benefits it can bring in terms of quality of orally inhaled product test data, and reductions in cost and effort associated with routine, critical measurements.